Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3467844 | 0.87 | CHRM1 (0.63) | CHRM1ALDH1A1HTTKCNH2KMT2A | |
| SCHEMBL3202010 | 0.84 | CHRM1 (0.58) | CHRM1LMNAALDH1A1KCNH2CASP6 | |
| SCHEMBL3202706 | 0.84 | CHRM1 (0.58) | CHRM1LMNAALDH1A1KCNH2CASP6 | |
| SCHEMBL3465898 | 0.84 | CHRM1 (0.50) | CHRM1LMNAALDH1A1MAPTKCNH2 | |
| SCHEMBL3466812 | 0.84 | CHRM1 (0.50) | CHRM1LMNAALDH1A1MAPTKCNH2 | |
| SCHEMBL4887369 | 0.82 | CHRM1 (0.51) | CHRM1LMNAALDH1A1MAPTHTT | |
| SCHEMBL4887392 | 0.82 | CHRM1 (0.51) | CHRM1LMNAALDH1A1MAPTHTT | |
| SCHEMBL3194265 | 0.80 | CHRM1 (0.56) | CHRM1KCNH2 | |
| SCHEMBL3194259 | 0.80 | CHRM1 (0.56) | CHRM1KCNH2 | |
| SCHEMBL4888549 | 0.79 | CHRM1 (0.67) | CHRM1LMNAALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678791-B2 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE IP VENTURES, L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | CHRM1 4498/4885GSTP1 464/4885GSTM2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.